Skip to Content

Cobicistat / darunavir / emtricitabine / tenofovir alafenamide and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with cobicistat / darunavir / emtricitabine / tenofovir alafenamide which include:

Moderate

darunavir food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Food enhances the absorption and oral bioavailability of darunavir administered in combination with low-dose ritonavir. The mechanism is unknown. When administered with food, the peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of darunavir were approximately 30% higher than when administered in the fasting state. Darunavir exposure was similar for the range of meals studied. The total caloric content of the various meals evaluated ranged from 240 Kcal (12 grams fat) to 928 Kcal (56 grams fat).

MANAGEMENT: To ensure maximal oral absorption, darunavir coadministered with ritonavir should be taken with food. The type of food is not important.

References

  1. "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.
Minor

tenofovir food

Minor Food Interaction

Information for this minor interaction is available on the professional version.

Cobicistat / darunavir / emtricitabine / tenofovir alafenamide drug interactions

There are 656 drug interactions with cobicistat / darunavir / emtricitabine / tenofovir alafenamide

Cobicistat / darunavir / emtricitabine / tenofovir alafenamide disease interactions

There are 11 disease interactions with cobicistat / darunavir / emtricitabine / tenofovir alafenamide which include:

More about cobicistat / darunavir / emtricitabine / tenofovir alafenamide

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.